Cargando…
Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
BACKGROUND: Hepatocellular carcinoma (HCC) recurrence rates following locoregional treatment are high. As multireceptor tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFRs) are effective in advanced HCC, we assessed the efficacy and safety of neoadjuvant systemi...
Autores principales: | Woei‐A‐Jin, F.J. Sherida H., Weijl, Nir I., Burgmans, Mark C., Fariña Sarasqueta, Arantza, van Wezel, J. Tom, Wasser, Martin N.J.M., Coenraad, Minneke J., Burggraaf, Jacobus, Osanto, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488766/ https://www.ncbi.nlm.nih.gov/pubmed/34251745 http://dx.doi.org/10.1002/onco.13901 |
Ejemplares similares
-
In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
por: Osanto, Susanne, et al.
Publicado: (2022) -
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Preoperative Imaging of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Meta-Analysis
por: van Kessel, Charlotte S., et al.
Publicado: (2012) -
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022) -
Patient reported outcome measure thresholds: The next step in the management of polycystic liver disease
por: Duijzer, Renée, et al.
Publicado: (2023)